Azenta, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Saxon from Needham reiterated a Buy rating on the stock and has a $42.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Saxon has given his Buy rating due to a combination of factors including Azenta’s strong financial performance in the fourth quarter of fiscal year 2025, where both revenue and EBITDA exceeded expectations. The company has also provided guidance for fiscal year 2026 that aligns with or surpasses market consensus, particularly in terms of EBITDA margins. Despite challenges in its end-markets, Azenta’s management is optimistic about the impact of strategic initiatives from the previous year, which are expected to enhance growth and profitability. Additionally, the anticipated sale of B Medical and the company’s ability to effectively manage capital allocation are seen as positive developments. The upcoming Investor Day on December 10, 2025, is also highlighted as a potential catalyst for the stock. These factors contribute to the reaffirmation of the Buy rating and an increased price target of $42.